Here Are the Facts You Need to Understand INMD

By Harris Dyer • Thursday, October 12 12:08 • Permanent Link

InMode marked a -23.1% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $21.53? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally.
InMode belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
The company's P/B ratio is 2.7
InMode has a trailing 12 month Price to Earnings (P/E) ratio of 10.0 based on its trailing 12 month price to earnings (EPS) of $2.15 per share
Its forward P/E ratio is 7.1, based on its forward earnings per share (EPS) of $3.04
INMD has a Price to Earnings Growth (PEG) ratio of 0.79, which shows the company is very undervalued compared to its earnings growth estimates.
Over the last four years, InMode has averaged free cash flows of $125.39 Million, which on average grew 0.0%
INMD's gross profit margins have averaged 85.2 % over the last four years and during this time they had a growth rate of -0.1 % and a coefficient of variability of 1.5 %.
InMode has moved -38.0% over the last year compared to 20.0% for the S&P 500 -- a difference of -58.0%
INMD has an average analyst rating of buy and is -61.13% away from its mean target price of $55.4 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.